Women Are Already Building India's AI Healthcare Systems. The Visibility Hasn't Caught Up.
The usual framing goes something like this: AI in healthcare is a big opportunity, and women in India should seize it. That framing is backwards. Women in India are not waiting for an opening in AI healthcare. They founded the companies, built the models, and ran the trials that define the sector today. The gap is not opportunity. It is who gets named, funded, and put in front of a room when the sector is discussed.
This distinction matters more than it sounds. Treating women's involvement in AI healthcare as a future possibility erases a decade of work already done, and it misdiagnoses the actual problem: not access, but visibility. The technology is not waiting to be built by women. It has been, for years, often by founders working with far less capital and far less press attention than the scale of their work would suggest.
The Diagnostics Record Already Exists
Start with Dr. Geetha Manjunath. A PhD from IISc, a former lab director at Xerox, she founded Niramai after a family member's late-stage breast cancer diagnosis raised an uncomfortable question: why does detection keep arriving too late for so many women. Niramai's radiation-free, AI-powered screening tool has become one of India's most cited healthtech exports, built and led by a woman, for a health problem that disproportionately affects women, in a country where breast cancer screening infrastructure remains thin outside major metros.
The pattern repeats beyond diagnostics into imaging infrastructure. Meenal Gupta, Noor Fatma, and Sheetal Tarkas founded Easiofy in 2022 to speed up medical imaging workflows using AI. Their platform, ImagiXAI, now processes more than a thousand scans a day across twelve Indian states, a direct answer to the radiologist shortage that slows diagnosis in tier-2 and tier-3 hospitals. Neither company got built because someone opened a door for its founders. They got built because a small group of women identified a specific systemic failure in Indian healthcare delivery and wrote the code to close it.
These are not isolated case studies. They are early data points in a sector that is about to scale sharply, and the timing matters for who gets credit for building it. Founders who are already several years into solving a problem hold an advantage that funding alone cannot replicate: they understand the clinical failure points better than anyone arriving later with more capital and less context.
The Market Is Scaling Fast, and the Builders Are Already in Place
India's AI-in-healthcare market was valued at roughly 436 million dollars in 2025 and is projected to grow at a compound annual rate above 29 percent through the next decade, reaching close to 4.8 billion dollars by 2034, according to industry market research. Growth is being driven by rising disease burden, an acute shortage of specialists relative to population, and a national push toward digitizing care delivery.
That national push has a name. In March 2026, the Indian government introduced the Strategy for AI in Healthcare for India, alongside a companion benchmarking initiative for validating health AI tools at scale. Together with the earlier National Digital Health Mission, these programs are explicitly designed to standardize how AI gets tested, approved, and deployed across Indian hospitals, public and private.
This is the moment sourcing infrastructure matters most. When a sector moves from early experimentation to standardized, government-backed scale, the people already positioned inside it, on panels, in press coverage, in investor pipelines, are the ones who define its next decade. Right now, that positioning is not matching who is actually building the technology. The founders with the clinical track record and the working products are frequently absent from the conversations that will shape how this sector regulates itself, funds itself, and tells its own story.
The Funding Number That Tells the Real Story
Here is what does not match the record of output above: women-led startups in India, across all sectors, have historically received less than 10 percent of total startup investment. Healthcare and healthtech, despite being sectors where women founders have shown disproportionately strong execution and revenue efficiency per dollar invested, have not been exempt from that pattern.
There are recent signs of correction. Industry reporting from the first half of 2026 points to women-led startups securing record levels of venture funding across fintech, health-tech, sustainability, and e-commerce, with healthtech founders specifically gaining traction in telemedicine and affordable-access tools. That is real progress. It is also evidence for the underlying argument rather than against it: when sourcing and investor attention actually reach women-led healthcare companies, funding follows quickly, which means the earlier gap was never about the quality of what was being built. It was about who was in the room being considered in the first place.
The lesson for anyone building sourcing infrastructure, whether that is a fund, a conference, or a media platform, is direct. The founders were always there. What changed was who went looking.
Where the Ground Is Shifting Next
Diagnostics and imaging remain the strongest track record. AI-assisted screening and imaging workflow tools are where Indian women founders currently have the clearest, most cited body of work, driven by direct, often personal, experience with gaps in the country's screening infrastructure.
Hospital-scale throughput is the next frontier. Tools like ImagiXAI point to a pattern beyond new diagnostic categories: AI infrastructure solving India's radiologist and specialist shortage at the operational level, across states and hospital tiers, not just at flagship urban institutions.
Maternal and reproductive health remain underbuilt. Founders are increasingly directing AI tools at conditions and health gaps that generalist, often male-led, health-tech has historically deprioritized, from maternal risk prediction to fertility diagnostics.
Policy and ethical oversight are catching up to the technology. As India's AI governance framework matures through initiatives like SAHI and BODH, and as India plays a growing role in shaping international AI governance discussions, women in health policy and bioethics are increasingly shaping how clinical AI gets regulated, not only how it gets built.
Mental health and telemedicine access are scaling in parallel. As AI-enabled teleconsultation and mental health platforms expand into underserved geographies, women-led health-tech ventures are a visible part of that expansion, particularly in affordable and rural-access models. This is where the next generation of category-defining Indian health-tech companies is likely to emerge, built by founders who are, once again, unlikely to wait for an invitation.
Why the Sourcing Gap Persists Even as the Sector Matures
It would be simple to assume that a maturing, government-backed sector automatically corrects for who gets visibility. In practice, the opposite tends to happen first. As standards, funding rounds, and media coverage consolidate around a smaller set of recognizable names, early movers who were not already in that circle can find it harder, not easier, to break in, even as their products scale. This is a familiar pattern across Indian tech more broadly: the infrastructure that decides who is credible tends to reference itself, pulling from the same investor networks, the same panel rosters, and the same journalist contact lists, long after the on-the-ground work has moved past what those networks reflect.
That is precisely why sourcing is a structural fix rather than a goodwill gesture. A verified, actively maintained database of women already leading in AI healthcare does something a single feature article cannot: it gives investors, journalists, and event organizers a starting point that does not depend on already knowing the right names. Without that infrastructure, visibility keeps flowing to whoever was visible last time, regardless of who is actually building the next diagnostic tool, the next imaging platform, or the next maternal health model. With it, sourcing becomes a search rather than a guess.
What "Opportunity" Language Gets Wrong
Framing this moment as an opportunity for women implies the sector is waiting for them to show up. It is not. The founders named in this piece are already years into building companies that function, scale, and solve documented clinical problems at national scale. What is missing is not ambition, technical skill, or market fit. It is the infrastructure that connects these women to the funding conversations, speaking panels, and press cycles where India's AI healthcare narrative actually gets written and repeated.
That is a sourcing problem, not a talent problem, and sourcing problems have sourcing solutions: better discovery systems, better verified expert databases, and editors, investors, and event organizers willing to look past the same small set of names that keep circulating. The next decade of India's AI healthcare story is already being written by the founders above. The only open question is whether the systems that decide who gets heard catch up in time to reflect it accurately.
The answer will not come from more listicles about future potential. It will come from the slower, less glamorous work of building sourcing infrastructure that actually reflects who is doing the work right now, updated as often as the sector itself changes. Until that infrastructure exists at scale, the founders profiled here will keep doing what they have always done: building first, and waiting, usually far too long, to be recognized for it.